Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease.
Parkinson’s disease
inhaled levodopa
levodopa dry-powder inhalation
off periods
Journal
Therapeutic advances in chronic disease
ISSN: 2040-6223
Titre abrégé: Ther Adv Chronic Dis
Pays: United States
ID NLM: 101532140
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
03
2019
accepted:
23
05
2019
entrez:
2
7
2019
pubmed:
2
7
2019
medline:
2
7
2019
Statut:
epublish
Résumé
Inhaled levodopa may quickly resolve off periods in Parkinson's disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler. A single-centre, single-ascending, single-dose-response study was performed. Over three visits, eight Parkinson's disease patients (not in the 'off state') received by inhalation 30 mg or 60 mg levodopa, or their regular oral levodopa. Maximum levodopa plasma concentration ( After inhalation, levodopa Inhaled levodopa is well tolerated, absorbed faster than oral levodopa, and can be robustly administered over a range of inhalation flow profiles. It therefore appears suitable for the treatment of off periods in Parkinson's disease.
Sections du résumé
BACKGROUND
BACKGROUND
Inhaled levodopa may quickly resolve off periods in Parkinson's disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
METHODS
METHODS
A single-centre, single-ascending, single-dose-response study was performed. Over three visits, eight Parkinson's disease patients (not in the 'off state') received by inhalation 30 mg or 60 mg levodopa, or their regular oral levodopa. Maximum levodopa plasma concentration (
RESULTS
RESULTS
After inhalation, levodopa
CONCLUSION
CONCLUSIONS
Inhaled levodopa is well tolerated, absorbed faster than oral levodopa, and can be robustly administered over a range of inhalation flow profiles. It therefore appears suitable for the treatment of off periods in Parkinson's disease.
Identifiants
pubmed: 31258882
doi: 10.1177/2040622319857617
pii: 10.1177_2040622319857617
pmc: PMC6589987
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2040622319857617Déclaration de conflit d'intérêts
Conflict of interest statement: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The employer of PH, AB and HWF receives royalties from the sales of the Cyclops DPI. FG is currently partly employed by PureIMS BV, the manufacturer of the Cyclops DPI.
Références
Mov Disord. 2002;17 Suppl 3:S28-40
pubmed: 11948753
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Proc Am Thorac Soc. 2004;1(4):338-44
pubmed: 16113455
Clin Ther. 2005 Nov;27(11):1710-24
pubmed: 16368444
Clin Pharmacokinet. 2006;45(2):109-36
pubmed: 16485914
CNS Drugs. 2007;21(8):677-92
pubmed: 17630819
Expert Opin Pharmacother. 2007 Nov;8(16):2799-809
pubmed: 17956200
CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):670-84
pubmed: 21838677
J Neurol Sci. 2012 Aug 15;319(1-2):86-8
pubmed: 22632782
Parkinsonism Relat Disord. 2013 Mar;19(3):339-45
pubmed: 23287001
Inhal Toxicol. 2013 Mar;25(4):219-32
pubmed: 23480198
Neuropsychiatr Dis Treat. 2013;9:321-40
pubmed: 23487540
Mov Disord. 2015 Jan;30(1):64-72
pubmed: 25449210
Eur J Pharm Biopharm. 2015 Feb;90:8-15
pubmed: 25615881
PLoS One. 2015 Jul 14;10(7):e0132714
pubmed: 26173114
Eur J Pharm Biopharm. 2015 Nov;97(Pt A):22-9
pubmed: 26453913
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
PLoS One. 2016 Mar 09;11(3):e0149768
pubmed: 26959239
Sci Transl Med. 2016 Oct 12;8(360):360ra136
pubmed: 27733560
Br J Clin Pharmacol. 1989 Jul;28(1):61-9
pubmed: 2775615
Mov Disord. 2018 Aug;33(8):1248-1266
pubmed: 29570866
Clin Neuropharmacol. 1986;9(2):153-9
pubmed: 3085927
Ann Neurol. 1985 Nov;18(5):537-43
pubmed: 4073849
Med Sci Sports Exerc. 1982;14(5):377-81
pubmed: 7154893
Neurology. 1993 Feb;43(2):367-71
pubmed: 8437704
Eur Respir J Suppl. 1993 Mar;16:5-40
pubmed: 8499054